- Home
- LXEH vs MTNB Comparison
LXEH vs MTNB Comparison
Compare LXEH & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.23
HOLD
Current Price
$0.76
Company Overview
Basic Information| Metric | LXEH | MTNB |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXEH | MTNB |
|---|---|---|
| Price | $0.23 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 189.8K | 35.6K |
| Earning Date | 12-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.47 |
| 52 Week High | $50.08 | $3.09 |
Technical Indicators
Market Signals| Indicator | LXEH | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 26.63 | 37.21 |
| Support Level | $0.27 | $0.71 |
| Resistance Level | $0.31 | $0.79 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 14.95 | 17.71 |
Price Performance
Historical Comparison LXEH
MTNB
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.